Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 3044-3051

  Berger, Raanan ^a   Rotem Yehudar, Rinat ^b   Slama, Gideon ^b   Landes, Shimon ^b   Kneller, Abraham ^a   Leiba, Merav ^a   Koren Michowitz, Maya ^a   Shimoni, Avichai ^a   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b CureTech Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CT 011; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; PROTEIN PD1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY BAT; PDCD1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLURRED VISION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG HALF LIFE; DYSPNEA; FEMALE; FLUSHING; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MALE; MAXIMUM PLASMA CONCENTRATION; NONHODGKIN LYMPHOMA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; WEAKNESS; WOUND; BLOOD DISEASE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

EID: 49649114804     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4079     Document Type: Article

References (15)

1. Chen L Co-inhibitory molecules of the B7-28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-47.
2. Tsushima F, Yao S. Shin T et al. Interaction between B7-1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007;110:180-5.
3. Latchman Y, Wood CR, ChernovaT, et al. PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. Nat Immunol 2001:2:261-8.
4. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000:192:1027 34
5. Tamura H, Dong H. Zhu G. et al. B7-1 costimulation preferentially enhances CD28-independentT helper cell function. Blood 2001;97:1809-16
6. Hardy B, Galli M. Rivlin E. Goren L. NovogrodskyA Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein. Cancer Immunol Immunother 1995;40:376-82.
7. Hardy B, Kovjazin R, RaiterA, Ganor N, Novogrodsky A. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc Natl Acad Sci USA 1997;94:5756-60.
8. Hardy B.Yampolski I, Kovjazin R, Galli M, Novogrodsky A. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. Cancer Res 1994;54:5793-6.
9. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway toT-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007:56:739-45.
10. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-1 promotesT-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8: 793-800.
11. IwaiY, Ishida M.TanakaY, OkazakiT, HonjoT, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7.
12. Strome SE, Dong H, Tamura H, et al. B7-1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003;63: 6501-5.
13. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003;63:7462-7.
14. Dong H, Chen L B7-1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003;81: 281-7.
15. Goldberg MV, Maris CH, Hipkiss EL, et al. Role of PD-1 and its ligand, B7-1 in early fate decisions of CD8Tcells. Blood 2007;110:186-92.